VRNA vs. COR

Last updated Jul 25, 2026

VRNA (Verona Pharma plc) and COR (Cencora Inc.) are both stocks. Both are in the Healthcare sector — VRNA in Biotechnology, COR in Medical Distribution. At a 0.03 correlation, their price movements are largely independent.

Performance

VRNA vs. COR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verona Pharma plc (VRNA) and Cencora Inc. (COR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

VRNA

• 1D: —
• 1M: —
• 6M: —
• YTD: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —
• ALL TIME*: —

COR

• 1D: 1.58%
• 1M: 8.94%
• 6M: -11.98%
• YTD: -7.88%
• 1Y: 7.50%
• 3Y*: 18.33%
• 5Y*: 22.41%
• 10Y*: 17.10%
• ALL TIME*: 17.71%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
COR Cencora Inc.	$409.08M	$456.15M	$501.76M

VRNA vs. COR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%
COR Cencora Inc.	-7.88%	51.48%	10.37%	25.33%	26.26%	44.09%	23.37%	23.51%	-17.57%	14.55%

Correlation

The correlation between VRNA and COR is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.04
Correlation (3Y) Calculated over the trailing 3-year period	-0.03
Correlation (5Y) Calculated over the trailing 5-year period	0.03
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.03

Fundamentals

Market Cap VRNA : $9.72B COR : $60.29B
EPS VRNA : -$0.69 COR : $13.08
PS Ratio VRNA : 57.97 COR : 0.18
PB Ratio VRNA : 34.92 COR : 17.82
Total Revenue (TTM) VRNA : $167.65M COR : $328.68B
Gross Profit (TTM) VRNA : $159.52M COR : $11.66B
EBITDA (TTM) VRNA : -$40.86M COR : $3.64B

Return for Risk

VRNA vs. COR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

COR

COR Risk / Return Rank: 53
COR Sharpe Ratio Rank: 57
COR Sortino Ratio Rank: 49
COR Omega Ratio Rank: 53
COR Calmar Ratio Rank: 54
COR Martin Ratio Rank: 55

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRNA vs. COR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Cencora Inc. (COR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	VRNA	COR	Difference
Sharpe ratio: Return per unit of total volatility	—	0.24	—
Sortino ratio: Return per unit of downside risk	—	0.49	—
Omega ratio: Gain probability vs. loss probability	—	1.08	—
Calmar ratio: Return relative to maximum drawdown	—	0.23	—
Martin ratio: Return relative to average drawdown	—	0.55	—

Drawdowns

Drawdown Indicators

	VRNA	COR	Difference
Max Drawdown Largest peak-to-trough decline	—	-71.01%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-32.44%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-32.44%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-32.44%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-32.44%	—
Current Drawdown Current decline from peak	—	-16.98%	—
Average Drawdown Average peak-to-trough decline	—	-13.65%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	13.64%	—

Volatility

Volatility by Period

	VRNA	COR	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	7.34%	—
Volatility (6M) Calculated over the trailing 6-month period	—	27.82%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	30.86%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	22.46%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	27.54%	—

Dividends

VRNA vs. COR - Dividend Comparison

VRNA has not paid dividends to shareholders, while COR's dividend yield for the trailing twelve months is around 0.76%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
COR Cencora Inc.	0.76%	0.67%	0.93%	0.96%	1.13%	5.13%	6.74%	7.48%	2.07%	1.61%	1.77%	1.17%
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

VRNA vs. COR - Profitability Comparison

The chart below illustrates the profitability comparison between Verona Pharma plc and Cencora Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Portfolio components

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

COR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Cencora Inc. reported a gross profit of 3.59B and revenue of 78.36B. Therefore, the gross margin over that period was 4.6%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

COR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Cencora Inc. reported an operating income of 1.14B and revenue of 78.36B, resulting in an operating margin of 1.5%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

COR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Cencora Inc. reported a net income of 1.64B and revenue of 78.36B, resulting in a net margin of 2.1%.

Frequently Asked Questions

Can I hold both VRNA and COR in my portfolio?

VRNA and COR have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.